Dear Colleagues,
On behalf of the Organizing Committee, we welcome you to the 11th Canadian Conference on Ovarian Cancer Research. We are thrilled to welcome you to Halifax and the Lord Nelson Hotel from May 24-26, 2024.
CCOCR 2024 will continue the tradition of bringing together expertise in ovarian cancer, providing a venue for networking between clinical specialists, researchers, trainees, and patient partners in research. We look forward to vibrant discussions and social opportunities to establish and expand our collaborative network.
CCOCR welcomes international participants interested in all types of ovarian cancer research. Participants and speakers will include those with interests in medicine and research spanning discovery, translational, clinical trials, and population health. CCOCR 2024 will also have many opportunities for trainees to learn the fundamentals of all disciplines in ovarian cancer research, present their work, and meet with patients and experts in ovarian cancer. Patients, caregivers and those with lived experience with ovarian cancer will be welcomed to join in a program that weaves the scientific program together with symposia focused and for our patient partners. Programming will integrate patient partners with other meeting delegates and provide opportunities for networking and learning.
Halifax is the vibrant capital city of Nova Scotia, and as one of Canada’s oldest cities, has a rich history. Participants can enjoy museums such as the Pier 21 Museum of Immigration, Halifax Citadel National Historic Site and the Maritime Museum of the Atlantic. As a port city, ocean views abound! Come and enjoy a beautiful and lively waterfront boardwalk. The Lord Nelson Hotel is located within walking distance of Halifax’s downtown amenities, including restaurants, nightlife and shopping, and across the street from Halifax’s beautiful public gardens.
We look forward to welcoming old and new colleagues alike for this exciting conference!
Jeanette Boudreau, Ph.D., Dalhousie University
Katharina Kieser, M.D., Dalhousie University
Tania Vrionis, CEO, Ovarian Cancer Canada